Stephen Gardner to Drug Therapy, Combination
This is a "connection" page, showing publications Stephen Gardner has written about Drug Therapy, Combination.
Connection Strength
0.247
-
A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects. Liver Int. 2014 Jul; 34(6):e89-95.
Score: 0.099
-
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol. 2008 May; 48(5):728-35.
Score: 0.067
-
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology. 2002 Jul; 36(1):186-94.
Score: 0.045
-
Pharmacokinetic properties of single-dose lamivudine/adefovir dipivoxil fixed-dose combination in healthy Chinese male volunteers. Clin Ther. 2013 Jan; 35(1):68-76.
Score: 0.023
-
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004 Jan; 126(1):81-90.
Score: 0.013